Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)
PHASE1
Background:
Adult T-cell leukemia (ATL) is a rare blood cancer. Researcher...
Status
Completed
Location
National Institutes of Health Clinical Center, 9000 Rockville Pike